ZYUS reports Phase 2a UTOPIA-1 data showing clinically relevant pain signals and reduced rescue opioid use with Trichomylin in advanced cancer pain.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
ZYUS Life Sciences reported topline Phase 2a data showing that Trichomylin® softgel capsules produced clinically relevant pain-response signals across multiple measures in patients with advanced cancer and moderate to severe cancer-related pain. The small single-arm study also identified a reduction in rescue opioid use during stable dosing, supporting further evaluation in controlled trials.
Phase 2a UTOPIA-1 Generates Efficacy and Opioid-Sparing Signals
The UTOPIA-1 trial (NCT06533657) enrolled 11 patients at three Canadian centers: McGill University Health Center, CancerCare Manitoba, and Centre Hospitalier de l’Université de Montréal. Participants continued standard-of-care pain management, including long-acting opioids, while receiving Trichomylin through an individualized titration regimen. The study evaluated dosing, safety, preliminary analgesic efficacy, quality of life, and opioid use.
The trial used a single-arm, proof-of-concept design. Although the registry initially allowed enrollment of up to 20 participants, the completed study enrolled 11.
Among all 11 treated patients, 91% successfully reached an individualized stable dose. No treatment-related serious adverse events were reported, supporting continued evaluation of the titration approach.
Among seven evaluable patients who adhered to the treatment and assessment schedule, the study showed clinically relevant improvement signals based on a predefined 30% threshold. 43% met the threshold for improvement in average pain, 29% for pain severity, and 57% for pain interference.
The analysis also identified signals of improvement in fatigue, insomnia and other measures of health-related quality of life. At the end of dosing, 29% of evaluable patients rated their overall condition as much improved, while another 57% reported minimal improvement.
Rescue Opioid Use Declined During Stable Dosing
The opioid-use findings provide a second clinically important signal. All seven evaluable patients had been prescribed rescue opioids for breakthrough pain, but two did not require rescue medication while receiving Trichomylin.
Among the five patients who used rescue opioids, approximately 79% of average rescue opioid use occurred during the titration phase, falling to approximately 6% during stable Trichomylin dosing.
Because this analysis involved only seven patients and was secondary to the study’s primary objectives, the finding cannot establish an opioid-sparing effect. However, it provides a rationale for formally evaluating opioid reduction in a larger randomized trial.
Cannabinoid Combination Targets Multiple Pain Pathways
Trichomylin is a fixed-dose combination containing delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabichromene (CBC). Public trial records identify the formulation as 5 mg of each component.
According to ZYUS, the formulation has preclinical activity across voltage-gated sodium channels, inflammatory pathways and the endocannabinoid system. The company is developing the product as a non-opioid adjunct to conventional pain management rather than as an immediate replacement for opioid therapy.
FDA Guidance Adds Regulatory Context
The findings come as the FDA continues to encourage development of non-opioid analgesics. Its May 2026 revised draft guidance identifies two priorities: advancing novel analgesic products and decreasing opioid exposure and preventing new addiction. The agency specifically discusses meaningful outcomes related to opioid use in development programs.
ZYUS plans to incorporate reduction in both long-acting and breakthrough opioid use as a co-primary endpoint alongside pain efficacy in a future controlled trial. This represents a proposed development strategy, not an FDA requirement or endorsement.
Next Development Stage
The company plans to advance Trichomylin into larger randomized controlled studies focused on safety, analgesic efficacy and opioid reduction. Final interpretation of UTOPIA-1 remains subject to completion of programmed analyses.
ZYUS also plans to present the results at the Montreal International Palliative Care Congress in October 2026 and submit the findings for peer-reviewed publication. The next clinical program will be important for determining whether the pain and opioid-use signals observed in this small Phase 2a study can be reproduced under randomized, controlled conditions.
Reference
ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer, Zyus Life Science, 1 October 2026
Unique Treatment of Oncology Pain in Advanced Cancer (UTOPIA-1), ClinicalTrials.gov ID NCT06533657
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.